GET DAILY SIGNALSLifeMD (LFMD) Falls -34.5% in 30 Days as Accounting Issues Surface
Key Takeaways
- LifeMD shares have declined roughly 34.5% over the last 30 days, falling from about $2.55 to near $1.67, extending a longer multi-month downtrend.
- The selloff accelerated after LifeMD disclosed it needed more time to file its quarterly report and correct historical financial statements.
- According to the company's late-filing notice, the corrections involve over-recognized revenue and under-recognized cost of revenue and general and administrative expenses for periods from 2024 through June 30, 2026.
- The disclosure prompted multiple securities-fraud investigations from shareholder law firms and drove the stock to its lowest levels in months.
- Over the last quarter, the stock has fallen roughly 50%, weighed down by disappointing second-quarter results and persistent concerns about profitability and cash burn.
- Weakness across telehealth peers and uncertainty ahead of the rescheduled third-quarter earnings report have compounded the selling pressure.
- For additional detail on valuation, results, and expectations, explore LifeMD's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-powered trading strategies are currently positioned across the market.
LifeMD (LFMD) Business Model and Competitive Position
LifeMD, Inc. operates as a direct-to-patient telehealth provider delivering virtual medical care and pharmacy services across the United States. Its vertically integrated platform links patients to a 50-state affiliated medical group, laboratory services, a nationwide home-delivery pharmacy, and a U.S.-based patient care center. Core brands include Rex MD for men's health, ShapiroMD for hair loss, plus services in primary care, women's health, weight management, and hormone therapy covering more than 200 conditions.
The company has focused on branded therapies and GLP-1 weight-management treatments instead of a compounding-heavy approach. Key partnerships, such as an exclusive arrangement with AT&T (T) offering complimentary memberships to eligible customers and collaborations with Novo Nordisk (NVO) and Eli Lilly (LLY) on weight-loss medications, form a central part of its growth story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors track the name for its telemedicine and GLP-1 exposure along with progress toward profitability.
LifeMD (LFMD) Recent Stock Price Moves: 30 Days and the Quarter
Over the last 30 days, LifeMD shares moved from a closing price of $2.55 on October 12, 2026, to roughly $1.67 in the latest session — a decline of about 34.5%. The drop was largely steady through October, with a brief rebound in early November before accelerating sharply on November 9 and 10, when the stock lost about 14.6% and 17% in consecutive sessions.
The longer-term picture looks weaker still. Over the last quarter, the stock fell from about $3.38 on August 11, 2026, to near $1.67, a drop of roughly 50%. The sustained downtrend reflects deteriorating sentiment rather than one isolated event, with selling pressure building after the August earnings report and intensifying after the November accounting disclosure.
Key Drivers Behind the Last 30 Days of Trading
The main catalyst was LifeMD's filing of a Form NT 10-Q (a Form 12b-25 late-filing notice) on November 9, 2026. The company stated it needed additional time to complete corrections to historical financial statements, citing the over-recognition of revenue and under-recognition of cost of revenue and general and administrative expenses for periods spanning 2024 through June 30, 2026. The announcement sent shares down as much as 14.56% intraday.
The disclosure triggered a wave of securities-fraud investigation announcements from law firms including Bronstein, Gewirtz & Grossman, Glancy Prongay Wolke & Rotter, and the Law Offices of Howard G. Smith, further pressuring investor confidence. Around the same time, LifeMD rescheduled its third-quarter earnings release and conference call, originally set for November 9, to November 12, 2026, adding to uncertainty. Selling continued the following session, with the stock falling another 17%.
Drivers of Performance Over the Past Quarter
The quarterly decline traces back to LifeMD's second-quarter report on August 5, 2026, when the company posted a loss of $0.16 per share, missing the roughly $0.15 consensus estimate, with revenue of about $47.28 million falling short of expectations. The miss reinforced concerns about ongoing losses, declining year-over-year revenue, and negative cash flow.
Analyst activity reflected a mixed but cautious tone. KeyBanc lowered its price target to $5 from $8, while B. Riley maintained a Buy rating with an $8 target. The consensus rating remained bullish, with an average 12-month target near $8, but targets carried little weight as the stock drifted lower. A positive September announcement of an exclusive AT&T collaboration — providing complimentary LifeMD memberships to eligible wireless and fiber customers — provided only temporary support, and broader weakness across telehealth peers added to the downward pressure.
LFMD Stock Forecast Drivers: What Comes Next
The most immediate focus is LifeMD's rescheduled third-quarter earnings report on November 12, 2026. Analysts expected a loss of roughly $0.14 per share on revenue near $48.8 million, down from $60.17 million in the prior-year quarter, so the actual results and any forward guidance will be closely scrutinized.
Investors should also monitor completion of the accounting corrections and the filing of the delayed quarterly report, along with any findings related to disclosure controls and internal controls over financial reporting. The outcome of the securities-fraud investigations and any potential class-action litigation represent additional overhangs. Beyond these near-term items, key themes include the adoption of GLP-1 weight-management offerings, the rollout of the AT&T partnership, progress toward adjusted-EBITDA profitability, and broader conditions in the telehealth and digital-health sectors. I'm watching this closely for any updates on those fronts.
Using AI Tools for Market Perspective
From what I see, automated strategies can provide useful context when individual stocks face volatility like this. I often review Tickeron's AI Trading Bots to compare how different models are positioned on names facing similar pressures, helping round out my own fundamental analysis without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
LFMD's RSI Oscillator slumps into oversold zone
The RSI Indicator for LFMD moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +9.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where LFMD advanced for three days, in 250 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
LFMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 51 cases where LFMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LFMD as a result. In 72 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for LFMD turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for LFMD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.356) is normal, around the industry mean (4.477). LFMD's P/E Ratio (-59.250) is considerably lower than the industry average of (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.788) is also within normal values, averaging (6.065).
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. LFMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement